Effects of Time-restricted Eating on Nutrient Absorption in Healthy Adults
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The obesity epidemic is well documented, and despite a complex etiology influenced by genetic, physiological, psychological, social, behavioral, and environmental factors, obesity seems to be the result of energy imbalance, where energy intake exceeds energy expenditure, regardless of the internal and external influences. Studies aiming to quantify and manipulate modulators of energy balance, including gastrointestinal (GI) energy absorption rates (i.e., digestibility), are crucial for reducing the incidence of overweight and obesity and improving overall human health. Despite considerable interindividual variability in the amount of ingested energy that is absorbed (~87-98% of ingested energy) by the gastrointestinal tract, generalized equations are used to calculate individual energy intake requirements, and the factors that contribute to such variability, including meal-timing, are largely unknown.
The proposed study seeks to determine the effects of restricting the eating window to 6-h (early time-restricted eating) as compared to a control eating window of 12 h on energy and macronutrient digestibility, thermic effect of food (TEF), postprandial blood metabolites (triglyceride, insulin, glucose, fructose, galactose, inositol, and sorbitol), 24 h glucose concentrations and glycemic variability, intestinal hydrogen gas production, microbiome composition, and gastrointestinal transit time in response to a controlled, energy balanced diet. In addition, this project will determine whether energy digestibility can be predicted from biological and physiological factors such as gut microbiota composition, gastrointestinal transit time, 24-h glucose concentrations, and postabsorptive and postprandial metabolomic profiles.
Participants will be randomized to early TRE (6-h feeding window, 8am-2pm) or a control eating schedule (12-h feeding window, 8am-8pm) and consume a controlled, energy balance diet (breakfast, lunch, dinner, snacks, and beverages) for 9 consecutive days before crossing over to the other intervention after at least a 3-wk washout for females (to control for hormonal fluctuations) and at least a 2-wk washout for males. Participants will collect stool and urine during each feeding phase. Gross energy content (heat combustion by bomb calorimetry) of the diet, stool, and urine samples will be used to calculate energy digestibility (diet gross energy - stool gross energy) and metabolizable energy. Factors that may mediate and/or predict energy digestibility efficiency, including gastrointestinal microbial composition, transit time, and gas production, fasting and postprandial metabolites, continuous glucose concentrations, and thermogenesis will be assessed.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Florida
-
Tallahassee, Florida, États-Unis, 32306
- Florida State University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- 20-45 years old
- Normal weight or overweight (18.5 to 29.9 kg/m2)
- Not taking any probiotics for 4 weeks prior to and throughout the entire study
- Willing to refrain from smoking, vaping, chewing tobacco, and dietary supplement use throughout the study
- Willing to consume a controlled diet for 9 consecutive days on 2 different occasions (18 days total) and collect all urine and fecal output for 3-5 days during each occasion
- Pass the blue dye gastrointestinal tracer (given at screening) within 72 hours of administration
Exclusion Criteria:
- Metabolic or cardiovascular abnormalities, gastrointestinal disorders, prior bariatric surgery, malabsorption, or any condition that interferes with metabolism (e.g., kidney disease, diabetes, cardiovascular disease, etc.)
- Suspected or known strictures, fistulas, or physiological/mechanical gastrointestinal obstruction
- Present condition of alcoholism, anabolic steroids, or other substance abuse issues
- Women who are pregnant, lactating, planning to become pregnant, or who have an irregular menstrual cycle in the past 6 months
- Weight fluctuations ± 5% of body weight in the last 6 months
- Allergies or intolerance to foods included in the controlled diet
- Any use of antibiotics, except topical antibiotics, within 3 months of study participation
- Colonoscopy within 3 months of study participation
- Use of laxatives, stool softeners, or anti-diarrheal medications more than once a week within 4-weeks of study enrollment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: early time-restricted eating (eTRE)
Participants will be provided a weight-maintenance diet for 9 consecutive days and will consume all meals and snacks in a 6-h window in the morning hours (e.g., 8:00 AM - 2:00 PM)
|
A diet meeting the participant's weight maintenance energy needs will be provided.
|
|
Expérimental: control eating schedule (CON)
Participants will be provided a weight-maintenance diet for 9 consecutive days and will consume all meals and snacks in a 12-h window in the morning hours (e.g., 8:00 AM - 8:00 PM)
|
A diet meeting the participant's weight maintenance energy needs will be provided.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Energy digestibility
Délai: Days 4-9
|
Calculated as gross energy of the diet (kcals) - gross energy excreted in stool (kcals)
|
Days 4-9
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fat digestibility
Délai: Days 4-9
|
Calculated as fat content of the diet - fat content excreted in stool
|
Days 4-9
|
|
Carbohydrate digestibility
Délai: Days 4-9
|
Calculated as carbohydrate content of the diet - carbohydrate content excreted in stool
|
Days 4-9
|
|
Protein digestibility
Délai: Days 4-9
|
Calculated as protein content of the diet - protein content excreted in stool
|
Days 4-9
|
|
Metabolizable energy
Délai: Days 4-9
|
Calculated as gross energy of the diet (kcals) - gross energy excreted in urine and stool (kcals)
|
Days 4-9
|
|
Metabolizable protein
Délai: Days 4-9
|
Calculated as protein content of the diet - protein excreted in urine and stool
|
Days 4-9
|
|
Postabsorptive and postprandial plasma metabolites
Délai: Day 6
|
Plasma metabolites will be measured using gas chromatography coupled with mass spectrometry in the postabsorptive state and following a standardized meal (1 hour, 2 hours, 3 hours, and 4 hours after meal intake).
|
Day 6
|
|
Gut microbiome
Délai: Day 6
|
Microbiota composition and diversity will be determined using 16S rRNA gene sequencing.
|
Day 6
|
|
Gastrointestinal transit time
Délai: Day 6
|
A gas-sensing capsule will be ingested to measure transit time in the gastrointestinal tract.
|
Day 6
|
|
Gastrointestinal gas production
Délai: Day 6
|
A gas-sensing capsule will be ingested to measure hydrogen, carbon dioxide, and oxygen production in the gastrointestinal tract.
|
Day 6
|
|
Gastrointestinal temperature
Délai: Day 6
|
A gas-sensing capsule will be ingested to measure temperature in the gastrointestinal tract.
|
Day 6
|
|
24-h glucose concentrations
Délai: Days 1-8
|
A continuous glucose monitor will be used to collect and assess 24-h glucose concentrations.
|
Days 1-8
|
|
24-h glucose variability
Délai: Days 1-8
|
A continuous glucose monitor will be used to collect and assess 24-h glucose variability.
|
Days 1-8
|
|
Thermic effect of food
Délai: Day 6
|
Indirect calorimetry measures will be collected in the resting state and for 4 hours (15-30, 45-60, 75-90, 105-120, 165-180, and 225-240 minutes) following the consumption of a standardized meal.
|
Day 6
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Claire E Berryman, Ph.D., Florida State University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- STUDY00001564
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .